{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"An infusion-related adverse event (AE) was defined as an AE occurring during infusion where the onset date and time of the event occurred within infusion time (+24 hours), and the event was judged as related to tisotumab vedotin by the investigator.","groups":[{"description":"Tisotumab vedotin 0.9 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).","id":"OG000","title":"Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg"},{"description":"Tisotumab vedotin 1.2 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).","id":"OG001","title":"Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Day 1, Day 8 & Day 15 (+1 day) until end of treatment (Part 1), approximately 48 weeks","title":"Part 1: Number of Participants Reporting One or More Infusion-related Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}